Abstract: A transport container for transporting a hub and vanes of a fan prior to assembly of the fan includes a body having a floor and defining an interior having a top opening. The transport container also includes a lid that removably covers the top opening. A divider wall is positioned within the interior so that the interior is divided into first and second internal compartments that hold the vanes of the fan. A hub post is positioned within the interior of the body. The hub post has a bottom end portion attached to the floor and a top end portion that is inserted into a central opening of the hub of the fan.

Abstract: A guitar positioning device, including a strip of resilient or flexible material, such as formed or molded from rubber, or polymer, can be adhered to the lower or lateral edges of the guitar, or banjo, in which it is used, while the exposed surface of the device will frictionally engage upon the legs of the musician, so as to prevent slippage of the instrument during its usage and application. The positioning device can be adhered by integral suction cups, at least two in number, or by an adhesive, a double sided tape, or even hook and pile fastening means, or rivet, in order to secure the positioning device to the exposed edge of the instrument that rests upon the legs of the musician, during a performance.

Abstract: A guitar positioning device, including a strip of resilient or flexible material, such as formed or molded from rubber, or polymer, can be adhered to the lower or lateral edges of the guitar, or banjo, in which it is used, while the exposed surface of the device will frictionally engage upon the legs of the musician, so as to prevent slippage of the instrument during its usage and application. The positioning device can be adhered by integral suction cups, at least two in number, or by an adhesive, a double sided tape, or even hook and pile fastening means, or rivet, in order to secure the positioning device to the exposed edge of the instrument that rests upon the legs of the musician, during a performance.

Abstract: A transport container for transporting a hub and vanes of a fan prior to assembly of the fan includes a body having a floor and defining an interior having a top opening. The transport container also includes a lid that removably covers the top opening. A divider wall is positioned within the interior so that the interior is divided into first and second internal compartments that hold the vanes of the fan. A hub post is positioned within the interior of the body. The hub post has a bottom end portion attached to the floor and a top end portion that is inserted into a central opening of the hub of the fan.

Abstract: A compound of Formula 1: (I) or salt thereof, as well as methods of making compounds of Formula 1, methods of using compounds of Formula 1 to treat proliferative disorders such as cancer, and related compounds, composition, and methods.

Abstract: Disclosed herein is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I: or a prodrug, or a pharmaceutically acceptable salt, or labeled with a detectable label or an affinity tag thereof; wherein R1, R1a, R100, R100a, R2, R200, W, B, and W1 are defined herein. Also disclosed are methods of using compounds of Formula I to treat proliferative disorders such as cancer.

Abstract: The present invention is directed towards an isomer, an enantiomer, a diastereoisomer, or a tautomer of a pyrrolidine compound represented by Formula I: in which the substituents R1, R1a, R2, R2a, R3, A and Q are defined herein; or a prodrug, or a salt thereof, and which bind to IAP BIR domains. In particular, the compounds are useful in treating proliferative disorders such as cancer.

Abstract: A compound of Formula 1: (I) or salt thereof, as well as methods of making compounds of Formula 1, methods of using compounds of Formula 1 to treat proliferative disorders such as cancer, and related compounds, composition, and methods.

Abstract: Disclosed herein is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I: or a prodrug, or a pharmaceutically acceptable salt, or labeled with a detectable label or an affinity tag thereof; wherein R1, R1a, R100, R100a, R2, R200, W, B, and W1 are defined herein. Also disclosed are methods of using compounds of Formula I to treat proliferative disorders such as cancer.

Abstract: The present invention, according to several embodiments, comprises a compound represented by Formula I: in which the substituents BG, B, B1, R1, R100, R2, R200, A, A1, Q and Q1 are defined herein; or a prodrug, or a salt thereof, and which bind to IAP BIR domains. In particular, the compounds of certain embodiments are useful in treating proliferative disorders such as cancer.

Abstract: Disclosed herein is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I: or a prodrug, or a pharmaceutically acceptable salt, or labeled with a detectable label or an affinity tag thereof; wherein R1, R1a, R100, R100a, R2, R200, W, B, and W1 are defined herein. Also disclosed are methods of using compounds of Formula I to treat proliferative disorders such as cancer.

Abstract: Disclosed is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I: or a salt thereof, in which R1, R2, R100, R200, A, A1, B, B1, BG, n, Q and Q1 are substituents described. Also disclosed is the use of compounds of Formula 1 to treat proliferative disorders.

Abstract: The present invention is directed towards an isomer, an enantiomer, a diastereoisomer, or a tautomer of a pyrrolidine compound represented by Formula I: in which the substituents R1, R1a, R2, R2a, R3, A and Q are defined herein; or a prodrug, or a salt thereof, and which bind to IAP BIR domains.

Abstract: Disclosed is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I: or a salt thereof, in which R1, R2, R100, R200, A, A1, B, B1, BG, n, Q and Q1 are substituents described. Also disclosed is the use of compounds of Formula 1 to treat proliferative disorders.

Abstract: The present invention is directed towards an isomer, an enantiomer, a diastereoisomer, or a tautomer of a pyrrolidine compound represented by Formula I: in which the substituents R1, R1a, R2, R2a, R3, A and Q are defined herein; or a prodrug, or a salt thereof, and which bind to IAP BIR domains. In particular, the compounds are useful in treating proliferative disorders such as cancer.

Abstract: A multi-mode wireless terminal device includes a first network interface for communicating with a first wireless network and a second network interface for communicating with a second wireless network. The second wireless network offers services that are not necessarily provided by the first wireless network. The multi-mode wireless terminal device acts as a gateway so that wireless terminal devices operating on the first wireless network may connect to the multi-mode wireless terminal device in order to access the services of the second wireless network. The multi-mode terminal device can limit access to the services based on operational parameters such as battery power level, wireless signal strength, usage time, processing load and the like.

Abstract: Disclosed herein is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I: or a prodrug, or a pharmaceutically acceptable salt, or labeled with a detectable label or an affinity tag thereof; wherein R1, R1a, R100, R100a, R2, R200, W, B, and W1 are defined herein. Also disclosed are methods of using compounds of Formula I to treat proliferative disorders such as cancer.

Abstract: Disclosed is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I: or a salt thereof, in which R1, R2, R100, R200, A, A1, B, B1, BG, n, Q and Q1 are substituents described. Also disclosed is the use of compounds of Formula 1 to treat proliferative disorders.

Abstract: A multi-mode wireless terminal device includes a first network interface for communicating with a first wireless network and a second network interface for communicating with a second wireless network. The second wireless network offers services that are not necessarily provided by the first wireless network. The multi-mode wireless terminal device acts as a gateway so that wireless terminal devices operating on the first wireless network may connect to the multi-mode wireless terminal device in order to access the services of the second wireless network. The multi-mode terminal device can limit access to the services based on operational parameters such as battery power level, wireless signal strength, usage time, processing load and the like.

Abstract: Disclosed is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I: or a salt thereof, in which R1, R2, R100, R200, A, A1, B, B1, BG, n, Q and Q1 are substituents described. Also disclosed is the use of compounds of Formula 1 to treat proliferative disorders.